204 related articles for article (PubMed ID: 29569163)
1. Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification.
Akagi Y; Yoshimoto K; Hata N; Kuga D; Hatae R; Amemiya T; Sangatsuda Y; Suzuki SO; Iwaki T; Mizoguchi M; Iihara K
Brain Tumor Pathol; 2018 Apr; 35(2):81-89. PubMed ID: 29569163
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of molecular analysis in diffuse glioma stratification.
Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
[TBL] [Abstract][Full Text] [Related]
3. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis.
Zheng L; Zhang M; Hou J; Gong J; Nie L; Chen X; Zhou Q; Chen N
Neuropathology; 2020 Dec; 40(6):599-605. PubMed ID: 32761642
[TBL] [Abstract][Full Text] [Related]
4. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
5. Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas.
Garton ALA; Kinslow CJ; Rae AI; Mehta A; Pannullo SC; Magge RS; Ramakrishna R; McKhann GM; Sisti MB; Bruce JN; Canoll P; Cheng SK; Sonabend AM; Wang TJC
J Neurosurg; 2020 May; 134(5):1357-1367. PubMed ID: 32384274
[TBL] [Abstract][Full Text] [Related]
6. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
Santosh V; Rao S
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M
Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683
[TBL] [Abstract][Full Text] [Related]
8. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
Ballester LY; Huse JT; Tang G; Fuller GN
Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
[TBL] [Abstract][Full Text] [Related]
9.
Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B
Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471
[TBL] [Abstract][Full Text] [Related]
10. MR textural analysis on T
Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z
J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
12. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
13. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
[TBL] [Abstract][Full Text] [Related]
15. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
[TBL] [Abstract][Full Text] [Related]
16. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
17. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
[TBL] [Abstract][Full Text] [Related]
18. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M
J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432
[TBL] [Abstract][Full Text] [Related]
19. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
20. [IDH、TERT and 1p/19q predicting clinical outcomes in patients with anaplastic oligodendroglioma].
Ji YC; Zhan YB; Liu XZ; Zhang ZY
Zhonghua Yi Xue Za Zhi; 2019 Jul; 99(25):1959-1962. PubMed ID: 31269600
[No Abstract] [Full Text] [Related]
[Next] [New Search]